CellProthera Advances ProtheraCytes Stem Cell Therapy to Phase III for Post-MI Heart Failure
核心洞察
CellProthera plans to initiate a Phase III trial in Q1 2027 for ProtheraCytes stem cell therapy targeting heart failure patients post-myocardial infarction.
The study will enroll 300-400 patients across 50 sites in the US and Europe, with potential expansion to Asia.
The therapy aims to repair damaged cardiac tissue and reduce scar formation without immunosuppressants, particularly benefiting 5-10% of patients with extensive cardiac damage.
CellProthera is preparing to launch a pivotal Phase III clinical trial for its stem cell therapy ProtheraCytes in patients with heart failure following myocardial infarction, with the study set to begin in Q1 2027. The biotech company plans to enroll between 300 and 400 patients at approximately 50 sites across the United States and Europe, with potential expansion into an Asian country.
Trial Design and Regulatory Progress
The Phase III study protocol was developed in collaboration with key opinion leaders in the heart failure and post-myocardial infarction field and has already received positive feedback from US regulators, according to CEO Matthieu de Kalbermatten. The trial will evaluate both the efficacy and safety of ProtheraCytes, which are designed to repair, protect, and promote regeneration and revascularization of damaged cardiac tissue.
Therapeutic Mechanism and Target Population
ProtheraCytes are engineered to function without requiring immunosuppressive therapy and aim to reduce scar tissue formation on the heart. This mechanism helps prevent organ expansion while enabling previously damaged tissue to regain contractile function. The therapy could prove particularly valuable for the 5-10% of patients who experience extensive cardiac tissue damage following a heart attack due to delayed treatment.
"These cells should be able to protect the tissue that's about to die by promoting its regeneration, as well as its revascularisation," Kalbermatten explained.
Precision Delivery Technology
To ensure therapeutic efficacy, CellProthera recently acquired rights to a transendocardial catheter from Celyad Oncology (搜索). This specialized device will enable direct delivery of CD34+ (搜索) stem cells to damaged cardiac tissue during the Phase III study. The catheter represents what Kalbermatten described as a "highly important" component of the trial, allowing for precise and accurate injection of stem cells around cardiac scar tissue.
While the catheter adds regulatory complexity, it will be integral to any future approval. CellProthera must first obtain CE mark certification for the device and plans comprehensive operator training programs, as the novel catheter is not routinely used in current heart failure treatments.
Manufacturing Strategy and Automation
Recognizing the operational challenges and high costs associated with scaling stem cell therapy production, CellProthera is implementing automation technologies to enable parallel batch production. The company plans to develop a "completely closed" system incorporating robotics to reduce production costs and streamline manufacturing processes.
Unlike many cell therapy companies that rely on contract development and manufacturing organizations (CDMOs), CellProthera is pursuing a self-sufficient approach by internalizing all manufacturing operations. This scale-out model aims to address the inherent challenges of producing cell therapies at commercial scale while maintaining cost-effectiveness.